<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77390">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02104245</url>
  </required_header>
  <id_info>
    <org_study_id>ARD-3150-1202</org_study_id>
    <nct_id>NCT02104245</nct_id>
  </id_info>
  <brief_title>Phase 3 Study With Pulmaquin in Non-CF Bronchiectasis</brief_title>
  <acronym>ORBIT-4</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of PulmaquinÂ® in the Management of Chronic Lung Infections With Pseudomonas Aeruginosa in Patients With Non-Cystic Fibrosis Bronchiectasis, Including 28 Day Open-Label Extension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aradigm Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Grifols Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aradigm Corporation</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study (ARD-3150-1201, ORBIT-4) will evaluate the safety and efficacy of inhaled
      Pulmaquin compared to inhaled placebo in subjects who have a confirmed diagnosis of
      non-cystic fibrosis (non-CF) bronchiectasis with a history of pulmonary exacerbations and
      chronic P. aeruginosa infections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multinational, multicenter, randomized, double-blind, placebo-controlled study to
      evaluate the safety and efficacy of Pulmaquin compared to placebo in the management of
      chronic lung infections with P. aeruginosa in subjects with non-CF bronchiectasis with a
      history of pulmonary exacerbations.

      This study will consist of a Screening Phase, a Double-Blind Phase (6 cycles each consisting
      of 28-days once daily Pulmaquin or Placebo, and 28 days off treatment) followed by
      Open-Label Extension (28 days on Pulmaquin).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to first pulmonary exacerbation (from baseline)</measure>
    <time_frame>48 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">255</enrollment>
  <condition>Non Cystic Fibrosis Bronchiectasis</condition>
  <arm_group>
    <arm_group_label>Pulmaquin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pulmaquin: Liquid mixture of liposomally encapsulated and unencapsulated ciprofloxacin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: Liquid formulation of empty liposomes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pulmaquin</intervention_name>
    <arm_group_label>Pulmaquin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of non-CF bronchiectasis

          -  History of P. aeruginosa respiratory infections

          -  At least two pulmonary exacerbations treated with antibiotics in the previous year

        Exclusion Criteria:

          -  Have a clinical diagnosis of CF

          -  Are pregnant
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juergen Froehlich, MD</last_name>
    <role>Study Director</role>
    <affiliation>Aradigm Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Debbie Pieretti</last_name>
    <email>pieretti@aradigm.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Duluth</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Rockhill</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 30, 2014</lastchanged_date>
  <firstreceived_date>March 28, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non Cystic Fibrosis Bronchiectasis, Pulmaquin, Ciprofloxacin, Pseudomonas aeruginosa</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bronchiectasis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ciprofloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
